relacorilant 100 MG Oral Capsule [Lifyorli]
- RxCUI
- 2739548
- RxNorm name
- relacorilant 100 MG Oral Capsule [Lifyorli]
- Display name
- relacorilant 100 MG Oral Capsule [Lifyorli]
- Full name
- relacorilant 100 MG Oral Capsule [Lifyorli]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:03
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Lifyorli | RELACORILANT | Corcept Therapeutics Incorporated | 6fcebfb5-19d6-4f63-b852-999d68a13729 | 2026-03-26 | Warnings, Adverse reactions | 2739548 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 6fcebfb5-19d6-4f63-b852-999d68a13729 | relacorilant 100 MG Oral Capsule [Lifyorli] | SBD | 1 | These highlights do not include all the information needed to use LIFYORLI safely and effectively. See full prescribing information for LIFYORLI. LIFYORLI TM (relacorilant) capsules, for oral use Initial U.S. Approval: 2026 | 20260326 |
| 6fcebfb5-19d6-4f63-b852-999d68a13729 | Lifyorli 100 MG Oral Capsule | SY | 1 | These highlights do not include all the information needed to use LIFYORLI safely and effectively. See full prescribing information for LIFYORLI. LIFYORLI TM (relacorilant) capsules, for oral use Initial U.S. Approval: 2026 | 20260326 |
| 6fcebfb5-19d6-4f63-b852-999d68a13729 | Lifyorli 100 MG Oral Capsule | PSN | 1 | These highlights do not include all the information needed to use LIFYORLI safely and effectively. See full prescribing information for LIFYORLI. LIFYORLI TM (relacorilant) capsules, for oral use Initial U.S. Approval: 2026 | 20260326 |